Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sean Raj

Diagnostic Radiology Dallas, TX Medical Doctor

NPI 1306137252 CMS profile 5330815

3500 Gaston Ave, Dallas, TX 75246

Open in the dashboard

General payments

$121,803

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Raj of Dallas, TX is reported in the CMS Open Payments database as having received $121,803 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,175 18
2024 General $6,940 10
2023 General $73,660 51
2022 General $235 4
2021 General $659 9
2020 General $131 2
2019 General $2 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Raj
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Sean Raj were reported at $40,175. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Sean Raj Diagnostic Radiology median Middle half National median
2019 $2 $108 $29–$318 $163
2020 $131 $65 $21–$252 $114
2021 $659 $92 $24–$292 $132
2022 $235 $104 $29–$294 $149
2023 $73,660 $110 $29–$337 $160
2024 $6,940 $113 $30–$356 $164
2025 $40,175 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Myriad Women's Health, Inc. $72,305 48 payments
  2. Siemens Medical Solutions USA, Inc. $25,752 9 payments
  3. Ge Healthcare $14,699 15 payments
  4. Myriad Genetic Laboratories, Inc. $6,200 5 payments
  5. Bard Peripheral Vascular, Inc. $1,155 2 payments
  6. Hologic Inc $312 5 payments
  7. Hologic, LLC $269 2 payments
  8. Volpara Solutions Inc $240 2 payments
  9. Endomagnetics Ltd $227 1 payment
  10. Inari Medical, Inc. $191 1 payment
  11. Other $452 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $72,400 45 payments
  2. Travel and Lodging $31,486 11 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,980 1 payment
  4. Honoraria $7,000 5 payments
  5. Food and Beverage $2,833 32 payments
  6. Entertainment $103 1 payment
Products named General payments · program years 2019–2025
  1. myRisk $77,705 52 payments
  2. Senographe Pristina $13,731 2 payments
  3. ACUSON Sequoia Diagnostic Ultrasound System $8,192 6 payments
  4. PRECISETUMOR $800 1 payment
  5. 3DIMENSIONS $548 5 payments
  6. Magseed $227 1 payment
  7. SELENIA DIMENSIONS 3D SYSTEM $216 2 payments
  8. FLOWTRIEVER CATHETER, S $191 1 payment
  9. CT THROMBECTOMY SYSTEM KIT $191 1 payment
  10. BREVERA BREAST BIOPSY SYSTEM $187 2 payments
  11. Other $902 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$133,137

Of which drugs: $190

Medicare patients

2,334

Average age 72

Services billed

6,013

2,287 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 50%
Osteoporosis 30%
Diabetes 23%
Chronic kidney disease 22%
Depression 22%
Ischemic heart disease 18%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadoterate meglumine, 0.1 ml A9575 Office 17 1,650 $146

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record